Digital Interventions in Type 2 Diabetes Mellitus

Lucía Salgueiro1*, Keiry Pereyra-Bencosme2, Cristian Vargas-Martínez3, Jorge Ortega-Márquez4, Santiago Callegari-Osorio5, Amanda Robasini-dos Santos6, Alberto Castro Molina7, Allan Vásquez-Bolaños8, Diego Olavarriá-Bernal9, Gabriel Soares-de Sousa10, Elaine Cristina Marqueze11, Cecília Mendes-de Sousa12

1 Servicio de Nutrición y Diabetes, Hospital General de Niños “Pedro de Elizalde”, Buenos Aires, Argentina; 2 Pontificia Universidad Católica Madre y Maestra, Santiago de los Caballeros, República Dominicana; 3 Servicio de Cirugía General, Clínica Las Vegas - Quirón Salud, Medellín, Colombia; 4 Universidad Nacional Autónoma de México, Ciudad de México, México; 5 Beth Israel Deaconess Medical Center, Boston, United States; 6 Hospital Brasilia, Secretaria de Saúde do DF, Brasilia, Brazil; 7 Universidad Autónoma de Guadalajara; 8 Facultad de Medicina, Universidad Francisco Marroquín, Guatemala; 9 Hospital de Clínicas José de Alencar, São Paulo, Brazil; 10 Serviços Médicos de Anestesia, Hospital Sírio-Libanês, São Paulo, Brazil; 11 Butantan Institute, São Paulo, Brazil; 12 Hospital Sírio Libanés, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil.

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic disease with an increasing mortality rate over the last decade. Diabetes self-management education (DSME) programs have been reported as essential to improve survival; however, patient adherence rates are very low. Therefore, digital devices have been created to deliver DSME at a distance and enhance program attendance. This study aims to assess the effects of digitally delivered DSME programs on the glycosylated hemoglobin (HbA1C) of patients with prediabetes and T2DM.

Methods: We researched PUBMED databases for randomized controlled trials (RCT) and observational studies (OS) published between 2012-2022 in English, Portuguese, or Spanish. The selected articles tested digital DSME interventions against treatment as usual (TAU) on adults (>18 years) previously diagnosed with T2DM or prediabetes. The result was measured by determining the HbA1c levels.

Results: Out of 261 articles, 14 RCTs were selected based on eligibility criteria. Digital DSME technologies have different objectives, including monitoring glycemic fluctuation, insulin titration, nutritional guidance, sleeping assessment, enhancement of physical activity, control of comorbidities, relevant task notifications, personalized treatment recommendations, educational content, and patient/medical staff remote interaction. Some of the technologies combined machine learning techniques for different functions, including detecting adverse glycemic events, physical activity, and blood pressure, among others. Although the level of adherence varied among the various trials, 4 of the 14 RCTs analyzed reported a significant reduction of HbA1c levels using these digital devices compared to TAU.

Discussion: Programs providing digital DSME education is a potentially cost-effective tool to improve diabetes care worldwide by overcoming distance barriers, facilitating physician-patient communication, and reducing HbA1c levels. Future improvements in implementing these technologies could enhance user compliance and contribute effectively to diabetes management.

Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease with a global prevalence of 10.5% among adults (Sun et al., 2022). Diabetes-related mortality has been increasing in the last decade, especially in developing countries (WHO, 2016).

The American Diabetes Association (ADA) strongly recommends a diabetes self-management education (DSME) program for patients with T2DM to achieve the skills needed for self-care management and decision-making (American Diabetes Association Professional Practice Committee, 2022b). Although this method has been demonstrated to improve the quality of life of these patients and to reduce glycosylated hemoglobin (HbA1c) levels, mortality risk, and health care costs (American Diabetes Association Professional Practice Committee, 2022b; Li et al., 2018); adherence rate is approximately 10% (Coningsby et al., 2022).

Recently, new digital instruments have been en-
Engineered to deliver DSME programs remotely cost-effectively, facilitating attendance and motivating more people with diabetes to participate in these activities (Bassi et al., 2021). Furthermore, these technologies have shown similar or even greater results regarding HbA1C reduction and patient engagement than in-person methods (American Diabetes Association Professional Practice Committee, 2022b). However, a comprehensive analysis of the available DSME programs still needs to be improved. Therefore, our objective is to review the effectiveness of the leading digital DSME tools in relation to HbA1c levels in adults with prediabetes or T2DM.

**Materials and Methods**

**Eligibility Criteria**

Randomized controlled trials (RCTs) or observational studies (OSs) that gathered all the following criteria were included in the analysis: 1) comparing a digital DSME device against in-person treatment as usual (TAU); 2) in adults (>18 years) diagnosed with T2DM or pre-diabetes according to ADA’s guidelines; 3) using HbA1c as an outcome; 4) and being written in English, Portuguese, or Spanish. Studies were excluded if they involved children or patients diagnosed with non-T2DM.

**Design and Data Sources**

This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Page et al., 2020). Digital Intervention was defined as using digital and technology resources to educate the patients about their disease, such as cellphones, tablets, tele-health, or other forms of web-based conferencing or interface for exchanging information about disease or health behaviors.

The following search strategy was conducted on 9th September 2022, using Medline database: (diabetes[Title]) AND ((Digital[tw]) OR (Digital platform-based[tw]) OR (Digital health tools[tw]) OR (Digital health intervention[tw]) OR (Digital health profession[tw]) OR (digital media[tw]) OR (Digital intervention self-management education[tw]) OR (Digital communication[tw]) OR (Digital educationassisted[tw]) OR (Digital education[tw]) OR (Digital education methods[tw]) OR (Digital technology[Mesh])). Filters: Clinical Study. Sort by: Most Recent.

**Data collection**

Two reviewers (LS and KPB) independently screened and reviewed the articles and extracted study data. A third author (CVM) resolved any disagreements. Data were generated by reporting the digital DSME interventions’ characteristics, their role in T2DM prevention, and their impact on HbA1c reduction and patient adherence. All data were organized into a table (table 1) and a narrative description.

**Data Extraction**

From the included studies, data on HbA1c was extracted as the primary outcome.

**Synthesis methods**

A qualitative systematic synthesis was performed using a critical interpretive method based on the studies’ key concepts, such as DSME technologies’ characteristics, effectiveness, and intervention adherence. The included articles are summarized in Table 1. The assessment of the risk of bias was evaluated by applying the Risk of Bias 2 (RoB2) tool, which is displayed in Figure 2. 58.3% of articles showed a low risk of bias, 16.7% raised some concerns, and 25% classified as at high risk. The features that represented an increased risk of bias were those related to the outcome analysis (measurement of the outcome and missing data) or a possible selection of the reported results.

**Results**

The study selection process is displayed in Figure 1, a flow diagram adapted from PRISMA’s guidelines. The initial search displayed 261 studies. Two authors (LS and KPB) reviewed the titles and abstracts of all 261 articles, excluding 208, for the following reasons: they were not related to diabetes (n = 146), were about gestational diabetes (n = 9), assessed type 1 Diabetes (n = 16), or did not evaluate digital interventions for DSME (n = 37). The same two authors (LS and KPB) excluded one report because of restricted access to the full text. Moreover, these two authors reviewed the full text of the 53 remaining articles, excluding 39 articles for the following reasons: they were protocols or ongoing trials (n = 16), did not assess the outcome of interest (n = 26), the control group did not receive in-person TAU (n = 2), there was no control arm (n = 1), the target population was not correct (n = 1), or did not assess digital interventions for DSME (n = 2). A third author (CVM) resolved any discrepancies. A total of 14 articles were eligible for full-text screening (Christensen et al., 2022; Farmer et al., 2021; Fortmann et al., 2017; Frias et al., 2017; Gong et al., 2020; Hilmarsdottir et al., 2020; Kassavou et al., 2020; Katula et al., 2022;
Figure 1: Flowchart adapted from the PRISMA flow diagram template.
Kleinman et al., 2017; Kulzer et al., 2018; Lee et al., 2022; McLeod et al., 2020; Middleton et al., 2021; Xu et al., 2020).

Discussion

Cases of T2DM have been increasing globally, resulting in higher costs. Management and follow-up of patients with chronic conditions such as T2DM solely based on direct patient interaction with their primary care physician can hinder the overall control and progression of the disease. They may result in insufficient management of the patient’s needs entirely. Using new technologies can result in better follow-up and control, resulting in patient compliance and adherence to the established treatments by their primary care physicians.

It is possible to extend the services offered by a healthcare system through digital health interventions. One clear example is the DSME interventions that can be achieved through the digital strategies discussed in this review.

DSME technologies have been reported to help manage patients with type 2 diabetes and cardiovascular risk factors. Although the management of glycemic levels has been reported to decrease the incidence of microvascular complications, macrovascular outcomes were not significantly different in patients with better glycemic control (King et al., 1999). In recent years, the strategy of reducing cardiovascular risk to reduce mortality and microvascular complications has received further attention (American Diabetes Association Professional Practice Committee, 2022b). Additionally, novel medications such as Liraglutide and, more recently, the Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors have reduced mortality by interfering with other biological pathways and moving beyond just the glycemic control (Lopaschuk & Verma, 2020; Marso et al., 2016). But all these pharmacological or non-pharmacological life-saving interventions only work if the patients adhere to the treatment regimen. Previous studies suggest that DSME is part of the multidisciplinary management required by the patients, which empowers them to participate in their disease monitoring actively.

Technology and data monitoring devices have been studied in patients with T2DM treated with insulin. These studies suggest that such devices facilitate personalized diabetes-care models, helping the physician in decision-making and encouraging patient communication with the healthcare team (Heinemann et al., 2020). However, most apps lack reinforcers for improving medication adherence (Huang et al., 2019).

There are some limitations in our study. Although
<table>
<thead>
<tr>
<th>Reference</th>
<th>Country</th>
<th>Study design(s)</th>
<th>Subjects</th>
<th>Study outcomes</th>
<th>Intervention (duration)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>United Kingdom</td>
<td>RCT (135)</td>
<td>Adults &gt; 18 years with either or both poorly controlled BP and glaucoma levels.</td>
<td>Changes in medication adherence, SBP, HbA1c (secondary outcome)</td>
<td>Highly targeted text message and interactive voice response intervention (12 months).</td>
<td>The HbA1c in the intervention group was 4.5 mmol/l lower compared to the control group (95% CI: -5.099 to -4.713). However, this study was not powered to detect significant between-group differences of HbA1c.</td>
</tr>
<tr>
<td>2</td>
<td>Denmark</td>
<td>RCT (170)</td>
<td>Patients aged 18–70 years (mean age of 56 years) with T2DM and a BMI between 30 and 45 kg/m².</td>
<td>Variations in body weight, HbA1c (secondary outcome), BMI, lipid profile, SBP, DBP, and GLP-1.</td>
<td>LRTA vs. LRTA+ (physicians, health care providers, and patients) an individualized digital lifestyle coaching program that includes a first face-to-face meeting with an individual health coach, which is followed by weekly synchronous online telephone meetings. Each patient and their health coach agree the lifestyle goals for the participant, who also sees LRA 20 to complete daily goal records, and to send comments to their personal health coach (6 months).</td>
<td>Of those patients with elevated HbA1c at baseline, 24 out of 62 (39%) adults from the intervention group normalized their HbA1c &lt; 6.5% at six months, compared to 8 out of 40 (20%) in the control group (p = 0.049). However, the reduction of HbA1c was still statistically significant.</td>
</tr>
<tr>
<td>3</td>
<td>South Korea</td>
<td>RCT (289)</td>
<td>Adults aged 15–74 years (mean age of 56 years) with T2DM, who also had HbA1c level of ≥7.5% and a BMI of 30.8 to 43.1 kg/m².</td>
<td>Changes in HbA1c (primary outcome), FBG, lifestyle behavior, body weight, BP, lipid profile, frequency of hypoglycemia, HOMA-IR and HOMA-B. In addition, the program satisfaction and adherence were assessed.</td>
<td>rCarD-games: electronic medical record-integrated mobile app that records patients' self-care data (SBHG, dietary habits, and step count), and sends automated text messages (educational, behavioral, and motivational messages) from the iCarD system to the participants' mobile phones (6 months).</td>
<td>The change in HbA1c levels did not differ significantly at 26 weeks (primary outcome) among the 3 groups: usual care (UC), mobile diabetes self-care (MC), and MC with personalized feedback. However, the reduction in HbA1c levels at 12 weeks was significantly different among the 3 groups: UC &gt; MC vs MC personalized feedback: -1.0% vs -0.8% vs -1.0% (p = 0.05).</td>
</tr>
<tr>
<td>4</td>
<td>USA</td>
<td>RCT (599)</td>
<td>Pre-diabetic volunteers (HbA1c 5.7%–6.4% [90–106 mmol/mol]) aged 21 to 80 years (mean age of 70.4 years).</td>
<td>Changes in HbA1c (primary outcome), body weight, cardiovascular risk factors.</td>
<td>The OmniHealth Program is a digital Diabetes Prevention Program (DPP), recognized by the CDC Diabetes Prevention Recognition Program. This is an asynchronous program that includes 12 months of novel interactive lessons, messages with a lifestyle health coach, virtual peer group discussions, and monitoring of meal, physical activity and weight (12 months).</td>
<td>At 12 months, the DPP group reduced significantly the HbA1c by an average of -0.23% (95% CI: -0.42% to -0.03%), compared with -0.10% (95% CI: -0.18% to -0.02%) for the control group (p=0.003) (primary endpoint).</td>
</tr>
<tr>
<td>5</td>
<td>South Africa, Malawi</td>
<td>RCT (116)</td>
<td>Adults &gt; 18 years (mean age of 57.1 years) with T2DM.</td>
<td>Differences in the levels of: HbA1c (primary endpoint), BP, lipid profile,</td>
<td>Motivational and educational text messages, three to four times per week (12 months).</td>
<td>SMBG text messages did not significantly improve glycemic control.</td>
</tr>
<tr>
<td>6</td>
<td>Australia</td>
<td>RCT (46)</td>
<td>Patients (mean age of 32.7 years) with young-onset T2DM (age of onset 18–40 years).</td>
<td>Variations in HbA1c (secondary outcome), lipid profile, SMBG data availability, and psychosocial well-being. Also, the adherence at scheduled clinical appointments was assessed.</td>
<td>Enhanced SMS Test Message-Based Expert and Knowledge Program: 18 supportive and/ or informative text messages per month, individualized for each subject depending on baseline characteristics like gender and smoking status (12 months).</td>
<td>There were no between-group differences in significant differences in HbA1c, BMI, lipid, or SMBG data (12 months).</td>
</tr>
<tr>
<td>7</td>
<td>Australia</td>
<td>RCT (187)</td>
<td>Adults aged 21 to 80 years (mean age of 57 years) with T2DM for less than 10 years.</td>
<td>Variations in HbA1c and health-related quality of life (HRQoL) (primary endpoint).</td>
<td>My Diabetes Coach (MDC) program consists in an interaction with the software assistant, Luna, which checks their blood glucose and additional information (12 months).</td>
<td>Although the HbA1c mean decreased in both arms at 12 months, there were not unusually significant differences between both groups (-0.04% vs -0.18% to -0.3% P=0.87).</td>
</tr>
</tbody>
</table>

Table 1: Summary of the articles included for the review.
8. McLeod et al., 2020 New Zealand RCT (62)
Patients aged 16-75 years (mean age of 62 years) with T2DM and prediabetes [HbA1c 41-70 mmol/mol (5.5-8.8%)], not taking insulin that were attended at the primary care level.
BeAT/Make program is: comprises four core components: (1) individual health coaching; (2) fortiﬁed provision of resources; (3) online peer support forum and (4) online goal tracking. Then maintenance activities (web-based peer support and goal tracking only) complete the intervention (12 months).
HbA1c levels at 12 months did not differ between study arms.

9. Hilmarsdottir et al., Iceland 2020 RCT (90)
Patients aged 18-75 years (mean age of 51.2 years) with T2DM.
Variations in HbA1c (primary outcome), blood lipids, body weight, as well as questions about distress related to diabetes.
Swiishand/balh smartphone app: a digital lifestyle program to enhance self-monitoring and the accomplishment of health goal settings in nutrition, physical activity, and stress management (12 months).
Although there were nonsigniﬁcant differences between groups, within the intervention group there was a signiﬁcant decrease in HbA1c from 61 ± 21.4 to 32.7 ± 15.2 mmol/L.

10. Xue et al., 2020 USA RCT (95)
Patients > 18 years (mean age of 54.3 years), with T2DM and a HbA1c value of >7%.
Changes in HbA1c and FBG (primary outcome). Also, the rate of response and engagement were measured.
Sipm/Diabetes is a: a subclinical platform that provides bidirectional pattern-provider communication through SMS and phone calls. It collects self-reported FBG, rating patient data to prioritize physician action (6 months).
The absolute reduction of HbA1c in the intervention group was 0.69% (95% CI, -1.41 to 0.02, p = 0.085), versus an absolute reduction of 0.05% in the control group (95% CI, -0.88 to 0.92, p = 0.946). Of those patients, with baseline HbA1c >8%, the intervention arm had a signiﬁcant decrease of 1.17% (95% CI, -1.30 to -0.44, p = 0.004), versus the control group that had a 0.0% non-signiﬁcant decrease (95% CI, -0.09 to 0.04, p = 0.97).

11. Kolker et al., 2018 Germany RCT (907)
Adults aged 25-84 years (mean age of 64 years) with T2DM and a HbA1c ≥7.5% using subcutaneous insulin therapy for 26 months.
Between groups differences in HbA1c levels (primary endpoint), therapy adjustments, frequency of hypoglycemic episodes and patient reported outcomes (like SMBG among others). Also, physician satisfaction was measured.
The integrated Personalized Diabetes Management (iPDM): it measures medication adherence, physical activity, and rest using digital ingestible sensors, wearable sensor patches, and a mobile app (12 weeks).
Although iPDM arm had a signiﬁcant greater reduction of HbA1c after 12 months versus usual care (<0.5%, p < 0.001 versus -1.3%, p < 0.0001, which represents a difference of 0.2%, p = 0.026).

12. Fitas et al., 2017 USA RCT (109)
Adults (mean age of 56.7 years) with SBP ≥140 mmHg and HbA1c ≥0%, failing antihypertensive (22 medications) and oral diabetes therapy.
Between groups differences in HbA1c levels (primary outcome), lipids, BP, and SMBG among others.
Between groups differences in: BP, HbA1c (secondary endpoint), SMBG, medication adherence, physical activity and rest.
Digital Medicine Obesity (DMO): it measures medication adherence, physical activity, and rest using digital ingestible sensors, wearable sensor patches, and a mobile app (12 weeks).
Although DMO group showed lower trends in HbA1c (as much as a 3% greater reduction), it had no signiﬁcantly differences in the reduction of HbA1c compared to usual care.

13. Fountman et al., 2017 USA RCT (126)
Hispanic adults aged 18 to 75 years (mean age of 46.4 years), with poorly controlled T2DM.
Between groups differences in HbA1c levels (primary outcome), lipids, BP, and SMBG among others.
Digital Diabetes: An mHealth test messages intervention for diabetes education and adherence (6 months).
As mHealth intervention had a statistically greater reduction in HbA1c compared with standard care (P = 0.016).

14. Kleiman et al., 2017 India RCT (91)
People aged 18 to 65 years (mean age of 48.4 years) with HbA1c between 7.5% and 12.5%.
Between groups differences in HbA1c levels (primary outcome), lipids, BP, medication adherence, diabetes self-care activities, diabetes distress, and diabetes knowledge.
An mHealth platform consisting of a smartphone app for patients, and a website and smartphone app for providers. The platform used reminders, data visualization, and support to increase self-care behaviors. The provider website had the medical history of each participant and a set of alerts for highlighting those participants who required more attention (6 months).
As 6 months the intervention group had a statistically signiﬁcant mean HbA1c decrease of 1.3%, versus 0.8% in the usual care group (p = 0.02), 95% CI mean difference: (1.0-1.6), with no statistically signiﬁcant differences after stratifying by gender, age, or length of time with T2DM.

**Table 1: Summary of the articles included for the review (continued).**
Pubmed is one of the most commonly used and ideal databases for reviewing biomedical electronic literature (Falagas et al., 2008), adding other databases would have broadened our study and included more studies. To reduce this bias, we developed a broad initial search strategy to screen many articles to be included in our review appropriately. However, another limitation is the final low number of pieces included because of our stringent criteria. Because of the high heterogeneity of the population and protocols used in this area of ongoing research, we decided to limit our scope further to increase the validity of our results. Despite including a limited number of studies, our results and conclusions are coherent with the existing literature (Mayberry et al., 2019; Pal et al., 2018; Sly et al., 2022). Finally, the use of HbA1c as a surrogate outcome might be statistically significant, although it might not reach a clinically significant improvement. Nonetheless, digital interventions that can improve HbA1c could also improve adherence, and lifestyle changes, among others; thus, the impact of an intervention with a subsequent improvement in HbA1c could also give rise to improvement in other areas outside the scope of this review.

Conclusions

Future research should focus on different patient populations to increase the adoption of diabetes self-management technologies. This is because the current technologies may not be accessible or user-friendly for everyone. Additionally, the differences in socio-cultural backgrounds and age groups among patients in different geographical locations can result in inconsistent results from various studies. Thus, the impact of these factors needs to be further investigated. Furthermore, multiple DSME technologies are designed for different purposes and approaches. However, there is currently no standard multidisciplinary approach for managing these patients. A standardized and effective intervention is needed to make DSME a viable option for healthcare providers in all income settings. In the future, randomized controlled trials that analyze specific DSME protocols as part of a comprehensive treatment plan may lead to the wider adoption of DSME in clinical practice.

Author Contributions

All the authors contributed equally to the conceptualization, methodology, systematic search, qualitative analysis, initial draft preparation, reviewing, and editing. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

We want to thank the PPCR team for the support and comments during the elaboration of the review.

Conflicts of Interest

The authors declare no conflict of interest.

References

- American Diabetes Association Professional Practice Committee. (2022b). 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes—2022. Diabetes Care, 45(Supplement_1), S60–S82. https://doi.org/10.2337/dc22-S005
- Farmer, A., Bobrow, K., Leon, N., Williams, N., Phiri, E., Namadingo, H., Cooper, S., Prince, J.,


• Xu, R., Xing, M., Javaherian, K., Peters, R., Ross, W., & Bernal-Mizrachi, C. (2020). Improving HbA1c with Glucose Self-Monitoring in Diabetic Patients with EpixDiabetes, a Phone